Profile data is unavailable for this security.
About the company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
- Revenue in MXN (TTM)16.49bn
- Net income in MXN1.10bn
- Incorporated1996
- Employees1.59k
- LocationGenomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeALVARO OBREGON 01210MexicoMEX
- Phone+52 5 550810000
- Fax+52 5 550810000
- Websitehttps://www.genommalab.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ouro Fino Saude Animal Participacoes SA | 3.10bn | -164.17m | 3.78bn | 1.01k | -- | 1.67 | -- | 1.22 | -0.9295 | -0.9295 | 17.54 | 12.78 | 0.7186 | 1.92 | 3.34 | -- | -3.81 | 5.93 | -4.69 | 7.48 | 45.88 | 49.30 | -5.30 | 7.80 | 2.67 | 39.69 | 0.3852 | 16.83 | -9.40 | 9.87 | -138.25 | -- | -0.2692 | 14.07 |
Blau Farmaceutica SA | 4.84bn | 781.65m | 6.31bn | 1.90k | 8.04 | 0.9414 | 6.85 | 1.30 | 1.33 | 1.33 | 8.24 | 11.37 | 0.5203 | 1.56 | 3.66 | 775,848.90 | 8.32 | 16.01 | 9.60 | 19.59 | 34.09 | 44.57 | 15.98 | 21.99 | 2.33 | -- | 0.2311 | 16.61 | -2.44 | 11.91 | -31.14 | 15.18 | 38.96 | -- |
Biomm SA | 388.26m | -266.54m | 7.52bn | -- | -- | 13.09 | -- | 19.38 | -0.9737 | -0.9737 | 1.42 | 1.38 | 0.3153 | 2.23 | 5.05 | -- | -21.64 | -19.78 | -28.31 | -24.35 | 19.68 | 20.27 | -68.65 | -95.65 | 1.01 | -10.77 | 0.5554 | -- | 12.62 | 137.44 | 12.34 | -- | 40.29 | -- |
Genomma Lab Internacional SAB de CV | 16.49bn | 1.10bn | 17.71bn | 1.59k | 15.16 | 1.68 | 13.14 | 1.07 | 1.14 | 1.14 | 17.28 | 10.34 | 0.764 | 2.90 | 3.66 | 10,095,660.00 | 5.09 | 5.79 | 8.21 | 8.64 | 62.23 | 61.70 | 6.67 | 7.88 | 1.32 | 2.55 | 0.3945 | 16.85 | -2.10 | 6.90 | -21.90 | -0.4465 | -26.37 | -- |
Hypera SA | 26.42bn | 5.60bn | 63.36bn | 9.00k | 11.40 | 1.65 | 9.87 | 2.40 | 2.67 | 2.67 | 12.60 | 18.50 | 0.3366 | 1.34 | 3.19 | -- | 7.13 | 8.29 | 8.64 | 9.98 | 62.47 | 63.49 | 21.18 | 26.01 | 1.37 | -- | 0.4798 | 50.18 | 4.88 | 16.27 | -3.30 | 7.74 | 29.83 | 10.24 |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 48.63m | 4.77% |
The Vanguard Group, Inc.as of 05 Apr 2024 | 29.05m | 2.85% |
MFS International (UK) Ltd.as of 31 Dec 2023 | 25.81m | 2.53% |
Skagen AS (Investment Management)as of 31 Mar 2024 | 25.00m | 2.45% |
BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 04 Apr 2024 | 20.72m | 2.03% |
BlackRock Fund Advisorsas of 04 Apr 2024 | 20.28m | 1.99% |
Wellington Management Co. LLPas of 31 Mar 2024 | 17.21m | 1.69% |
Lemanik Asset Management SAas of 30 Jun 2023 | 15.86m | 1.56% |
BlackRock M�xico Operadora SA de CV SOFIas of 29 Feb 2024 | 13.98m | 1.37% |
Dimensional Fund Advisors LPas of 04 Apr 2024 | 11.95m | 1.17% |